1. Home
  2. CFLT vs PRAX Comparison

CFLT vs PRAX Comparison

Compare CFLT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Confluent Inc.

CFLT

Confluent Inc.

HOLD

Current Price

$30.57

Market Cap

7.7B

Sector

Technology

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$307.97

Market Cap

8.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFLT
PRAX
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
8.8B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CFLT
PRAX
Price
$30.57
$307.97
Analyst Decision
Hold
Strong Buy
Analyst Count
31
13
Target Price
$29.40
$397.85
AVG Volume (30 Days)
8.6M
600.5K
Earning Date
02-11-2026
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,113,149,000.00
$7,463,000.00
Revenue This Year
$22.76
N/A
Revenue Next Year
$16.57
$14,827.76
P/E Ratio
N/A
N/A
Revenue Growth
21.57
364.98
52 Week Low
$15.64
$26.70
52 Week High
$37.90
$326.91

Technical Indicators

Market Signals
Indicator
CFLT
PRAX
Relative Strength Index (RSI) 75.46 61.83
Support Level $30.42 $266.93
Resistance Level $30.63 $326.83
Average True Range (ATR) 0.09 19.27
MACD -0.20 -0.68
Stochastic Oscillator 88.89 75.79

Price Performance

Historical Comparison
CFLT
PRAX

About CFLT Confluent Inc.

Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Share on Social Networks: